Table 2:

The upper portion of the table depicts the odds ratios for the baseline presence of brain metastasis at diagnosis. The lower portion of the table delineates sub-distribution hazard ratios for the subsequent development of brain metastasis on treatment. Cohorts are grouped by driver mutation. Bold denotes comparisons with statistically significant differences.

Baseline at time of diagnosis	Odds ratio	P-value
HER2 vs. KRAS	0.7	.33
HER2 vs. EGFR	0.5	.03
EGFR vs. KRAS	1.4	.24
HER2 YVMA vs. EGFR	0.5	.09
HER2 YVMA vs. KRAS	0.6	.28
HER2 YVMA vs. HER2 non-YVMA	1.0	.99
Subsequent development on treatment	Hazard ratio	P-value
HER2 vs. KRAS	5.2	<.001
HER2 vs. EGFR	1.7	.06
EGFR vs. KRAS	3.0	.001
HER2 YVMA vs. EGFR	1.8	.14
HER2 YVMA vs. KRAS	5.9	<.001
HER2 YVMA vs. HER2 non-YVMA	0.9	.60